Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular
Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with
sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate
the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC
under daily-life treatment conditions.